Càncer Signalling and Cell Cycle Laboratory

Angel R. Nebreda

Group Leader

ICREA Research Professor, ERC Advanced Grant

angel.nebreda@irbbarcelona.org

+34 93 40 31379

Research keywords

The Signalling and Cell Cycle Laboratory focuses on studying the basic mechanisms of cell regulation, especially regarding how external signals are interpreted by cells to modulate cell proliferation, differentiation and survival. Our research centers on two main subjects:

Mechanisms of signal integration by p38 MAP kinases and their role in cancer
Regulation and role of the RINGO/Speedy proteins, a new family of CDK activators.

Selected publications

Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells

Cánovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, Pérez-Montoyo H, Serra V, González-Suárez E, Stracker TH and Nebreda AR.

Cancer Cell, 33 (6), 1094-1110. (2018)

Induction of oxidative metabolism by the p38α/MK2 pathway

Trempolec N, Muñoz JP, Slobodnyuk K, Marin S, Cascante M, Zorzano A and Nebreda AR.

Sci Rep, 7 (1), 11367 (2017)

Essential role of the Cdk2 activator RingoA in meiotic telomere tethering to the nuclear envelope

Mikolcevic P, Isoda M, Shibuya H, del Barco Barrantes I, Igea A, Suja JA, Shackleton S, Watanabe Y and Nebreda AR.

Nat Commun, 7 11084 (2016)

Gene Dosage Imbalance Contributes to Chromosomal Instability-Induced Tumorigenesis

Clemente-Ruiz M, Murillo-Maldonado JM, Benhra N, Barrio L, Pérez L, Quiroga G, Nebreda AR and Milán M.

Dev Cell, 36 (3), 290-302 (2016)

The Stress Kinase p38α as a Target for Cancer Therapy

Igea A and Nebreda AR.

Cancer Res, 75 (19), 3997-4002 (2015)

Dual function of p38α MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival

Gupta J, del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG and Nebreda AR.

Cancer Cell, 25 (4), 484-500 (2014)

Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH

Urosevic J, Garcia-Albéniz X, Planet E, Real S, Céspedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M, Mangues R, Dolado I, Barriga FM, Nadal C, Kemeny N, Batlle E, Nebreda AR and Gomis RR.

Nat Cell Biol, 16 (7), 685-94 (2014)

Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK

Pereira L, Igea A, Canovas B, Dolado I and Nebreda AR.

EMBO Mol Med, 5 (11), 1759-1774 (2013)

SnapShot: p38 MAPK signaling

Trempolec N, Dave-Coll N and Nebreda AR.

Cell, 152 (3), 656-657 (2013)

SnapShot: p38 MAPK substrates

Trempolec N, Dave-Coll N and Nebreda AR.

Cell, 152 (4), 924-925 (2013)

Genetic analysis of specific and redundant roles for p38alpha and p38beta MAPKs during mouse development

del Barco Barrantes I, Coya JM, Maina F, Arthur JS and Nebreda AR.

P Natl Acad Sci Usa, 108 (31), 12764-9 (2011)

Mechanisms and functions of p38 MAPK signalling

Cuadrado A and Nebreda AR.

Biochem J, 429 (3), 403-17 (2010)

Funding

The Signalling and cell cycle laboratory receives financial support from the following sources:

European Research Council
Generalitat de Catalunya (Government of Catalonia)
Ministerio de Economía y Competitividad (MINECO)
European Commission (EC), Fondo Europeo de Desarrollo Regional (FEDER), "Una manera de hacer Europa"

Projects

"Regulacion de la tumorigénesis por quinasas de estrés: p38a en la homeostasis de las células tumorales y su interacción con las celulas del estroma" cofinanciado por el Ministerio de Economia y Competitividad y por el Fondo Europeo de Desarrollo Regional (FEDER). Referencia: SAF2016-81043-R (MINECO/FEDER, UE).

"Role of p38α MAPK in cancer cell metabolism during tumor development" financiado por el Worldwide Cancer Research (WCR). Referencia: 18-0666

Grup de Recerca consolidat (SGR 2017-2019) de la Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya. Agencia de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). Referencia: 2017 SGR 557

"Tumor immunosupression by myeloid p38a signaling; implications for melanoma therapy" financiado por la Fundación Científica AECC. Referencia: PROYE18035RODR

"Innovative therapeutic tools to ameliorate chemotherapy-induced cardiotoxicity" (p38_InTh), financiado por el European Research Council (ERC) mediante el Programa de Investigación e Innovación de la Unión Europea Horizonte 2020. Referencia: 825763